JP2024525512A5 - - Google Patents
Info
- Publication number
- JP2024525512A5 JP2024525512A5 JP2023581003A JP2023581003A JP2024525512A5 JP 2024525512 A5 JP2024525512 A5 JP 2024525512A5 JP 2023581003 A JP2023581003 A JP 2023581003A JP 2023581003 A JP2023581003 A JP 2023581003A JP 2024525512 A5 JP2024525512 A5 JP 2024525512A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- optionally
- condition
- chemically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202970P | 2021-07-01 | 2021-07-01 | |
| US63/202,970 | 2021-07-01 | ||
| PCT/US2022/035866 WO2023278799A1 (en) | 2021-07-01 | 2022-06-30 | Therapeutic nucleic acids and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525512A JP2024525512A (ja) | 2024-07-12 |
| JP2024525512A5 true JP2024525512A5 (https=) | 2025-07-07 |
Family
ID=84690648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023581003A Pending JP2024525512A (ja) | 2021-07-01 | 2022-06-30 | 治療用核酸及びその使用方法 |
| JP2023581043A Pending JP2024527340A (ja) | 2021-07-01 | 2022-06-30 | 核酸の経口送達用の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023581043A Pending JP2024527340A (ja) | 2021-07-01 | 2022-06-30 | 核酸の経口送達用の製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20250025487A1 (https=) |
| EP (2) | EP4363434A4 (https=) |
| JP (2) | JP2024525512A (https=) |
| KR (2) | KR20240028486A (https=) |
| CN (2) | CN117916249A (https=) |
| AU (2) | AU2022303384A1 (https=) |
| CA (2) | CA3223495A1 (https=) |
| WO (2) | WO2023278802A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| EP4494699A3 (en) | 2014-10-03 | 2025-04-30 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| JP2025534332A (ja) * | 2022-09-30 | 2025-10-15 | セダーズ－シナイ メディカル センター | 治療用核酸及びその使用方法 |
| AU2024340578A1 (en) * | 2023-09-15 | 2026-03-05 | Cedars-Sinai Medical Center | Trex-1 augmentation to attenuate genotoxic stress and exert cardioprotection |
| WO2026035744A1 (en) | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Combination therapies for metabolic disease |
| WO2026035943A1 (en) * | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Formulations for oral delivery of nucleic acids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| US20120301463A1 (en) * | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| WO2014152211A1 (en) * | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| ES2724549T3 (es) * | 2013-10-18 | 2019-09-12 | Inst Nat Sante Rech Med | ARN pequeños derivados de RNY como biomarcadores para trastornos relacionados con la aterosclerosis |
| EP3247716A4 (en) * | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| US20190365913A1 (en) * | 2016-02-04 | 2019-12-05 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| US11859234B2 (en) * | 2016-05-06 | 2024-01-02 | The Trustees Of Princeton University | Method of monitoring RNase L activity |
| US12258594B2 (en) * | 2018-12-05 | 2025-03-25 | The Broad Institute, Inc. | Cas proteins with reduced immunogenicity and methods of screening thereof |
| WO2020131986A1 (en) * | 2018-12-21 | 2020-06-25 | Pioneer Hi-Bred International, Inc. | Multiplex genome targeting |
-
2022
- 2022-06-30 WO PCT/US2022/035870 patent/WO2023278802A1/en not_active Ceased
- 2022-06-30 JP JP2023581003A patent/JP2024525512A/ja active Pending
- 2022-06-30 CN CN202280059708.7A patent/CN117916249A/zh active Pending
- 2022-06-30 KR KR1020247003755A patent/KR20240028486A/ko active Pending
- 2022-06-30 US US18/571,924 patent/US20250025487A1/en active Pending
- 2022-06-30 CA CA3223495A patent/CA3223495A1/en active Pending
- 2022-06-30 EP EP22834283.8A patent/EP4363434A4/en active Pending
- 2022-06-30 CA CA3223686A patent/CA3223686A1/en active Pending
- 2022-06-30 EP EP22834280.4A patent/EP4362954A1/en active Pending
- 2022-06-30 US US18/572,067 patent/US20240285668A1/en active Pending
- 2022-06-30 JP JP2023581043A patent/JP2024527340A/ja active Pending
- 2022-06-30 AU AU2022303384A patent/AU2022303384A1/en active Pending
- 2022-06-30 AU AU2022303330A patent/AU2022303330A1/en active Pending
- 2022-06-30 WO PCT/US2022/035866 patent/WO2023278799A1/en not_active Ceased
- 2022-06-30 CN CN202280059718.0A patent/CN117897162A/zh active Pending
- 2022-06-30 KR KR1020247003744A patent/KR20240027814A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525512A5 (https=) | ||
| US12377056B2 (en) | Cladribine regimen for treating multiple sclerosis | |
| JP2025501731A5 (https=) | ||
| JP6430554B2 (ja) | 多発性硬化症を治療するためのクラドリビン投薬計画 | |
| US20240285668A1 (en) | Formulations for oral delivery of nucleic acids | |
| JP2024527340A5 (https=) | ||
| JP2025500824A5 (https=) | ||
| JP2024517143A5 (https=) | ||
| EP4594489A2 (en) | Therapeutic nucleic acids and methods of use thereof | |
| EP0329609A2 (en) | Antiviral combination | |
| SK281806B6 (sk) | Použitie il-10 na prípravu liečiva na prevenciu diabetes mellitus | |
| JP2024515880A5 (https=) | ||
| JP4011618B2 (ja) | 複合治療におけるｔｎｆレセプター及びステロイドホルモン | |
| EP1325751A1 (en) | Novel drugs for liver diseases | |
| WO2022244825A1 (ja) | インフルエンザウイルス核酸脂質粒子ワクチン | |
| Siddiqui et al. | Intramuscular Interferon-β-1a: In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis | |
| WO2025188663A1 (en) | Methods for the treatment of diabetes-associated autonomic neuropathy | |
| AU2023373880A1 (en) | Recombinant il-12 albumin binding domain fusion proteins for use in methods for the treatment of cancer | |
| CN119661723A (zh) | 一种生长激素融合蛋白、核酸药物及其用途 | |
| JP2003137812A (ja) | 心不全の予防及び／又は治療剤 | |
| CN101500598A (zh) | 治疗多发性硬化症的克拉屈滨方案 | |
| WO2006091661A1 (en) | Compositions for and methods of modulating platelet levels | |
| HK1127753B (en) | Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis |